araag2/HINT huggingface dataset:
Clinical trial NCT00736151 (phase 2, status: completed)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: ralfinamide
SMILES: C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients

          -  Females post-menopausal for at least 12 months, 24 months in India, Poland, and
             Austria

          -  Diagnosed by neurologist with current neuropathic pain

        Exclusion Criteria:

          -  See inclusion criteria
Clinical trial NCT01131078 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin], capecitabine, irinotecan
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  colon or rectal cancer, with metastases;

          -  >=1 measurable lesion.

        Exclusion Criteria:

          -  previous systemic treatment for advanced disease;

          -  radiotherapy to any site within 4 weeks before study;

          -  daily aspirin (>325 mg/day), anticoagulants, or other medications known to predispose
             to gastrointestinal ulceration;

          -  co-existing malignancies or malignancies diagnosed within last 5 years (except basal
             cell cancer or cervical cancer in situ).
Clinical trial NCT00125788 (phase 2, status: completed)
Conditions: sickle cell anemia, thalassemia
ICD codes: D56.0, D56.1, D56.3, D56.9, D56.2, D56.5, D57.40
Drugs: l-glutamine, placebo
SMILES: N[C@@H](CCC(N)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        To be eligible to participate in the study, a patient must meet all of the following
        inclusion criteria:

          -  Patient is at least five years of age.

          -  Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia
             (documented by hemoglobin electrophoresis).

          -  Patient has had at least two episodes of painful crises within 12 months of the
             screening visit.

          -  If the patient has been treated with an anti-sickling agent within three months of the
             screening visit, the therapy must have been continuous for at least three months with
             the intent to continue for the next 14 months.

          -  Patient or the patient's legally authorized representative has given written informed
             consent.

          -  If the patient is a female of child-bearing potential, she agrees to practice a
             recognized form of birth control during the course of the study.

        Exclusion Criteria:

        If the patient meets any of the following criteria, the patient must not be enrolled:

          -  Patient has a significant medical condition that required hospitalization (other than
             sickle painful crisis) within two months of the screening visit.

          -  Patient has diabetes mellitus with untreated fasting blood sugar >115 mg/dL.

          -  Patient has prothrombin time International Normalized Ratio (INR) > 2.0.

          -  Patient has serum albumin < 3.0 g/dl.

          -  Patient has received any blood products within three weeks of the screening visit.

          -  Patient has a history of uncontrolled liver disease or renal insufficiency.

          -  Patient is pregnant or lactating.

          -  Patient has been treated with an experimental anti-sickling medication/treatment
             (except hydroxyurea) within 30 days of the screening visit.

          -  Patient has been treated with an experimental drug within 30 days of the screening
             visit.

          -  There are factors that would, in the judgment of the investigator, make it difficult
             for the patient to comply with the requirements of the study.
Clinical trial NCT00145600 (phase 2, status: active, not recruiting)
Conditions: hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: 12 week stanford v chemotherapy, 4 cycles of vamp chemotherapy, 2 alternating cycles of vamp/cop chemotherapy, 3 alternating cycles of vamp/cop chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Eligible patients must have histologically confirmed previously untreated Hodgkin's
             disease (Patients receiving limited emergent RT or steroid therapy because of
             cardiopulmonary decompensation or spinal cord compression will be eligible for
             protocol enrollment).

          -  Patients must be 21 years of age or younger

          -  Ann Arbor stages IIB-IV

          -  No prior treatment.

          -  No pregnant or lactating women.

          -  Signed informed consent

          -  If re-evaluation of a patient's disease shows favorable risk features or intermediate
             risk features, the patient will be removed from the HOD99 study and consented to the
             respective HOD08 or HOD05 study.

        Inclusion: treatment of favorable risk features:

          -  Ann Arbor IA or IIA with:

               1. Non-bulky mediastinal disease (<33% mediastinal to thoracic ratio on chest x ray)

               2. Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions
                  (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy
                  (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)

                  Inclusion: unfavorable risk features:

          -  Stage must be classified as one of the following:

               1. Ann Arbor stage IIB, IIIB, or any IV
Clinical trial NCT00449488 (phase 2, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Successful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by:

          -  chest pain suggestive for acute myocardial infarction

          -  symptom onset < 12 hour before hospital admission, or < 24 hour in case ongoing
             ischemia

          -  ECG with ST-T segment elevation > 1 mV in 2 or more leads

          -  TIMI flow 0/1 before primary PCI on diagnostic coronary angiography;

        Exclusion Criteria:

          -  Hemoglobin levels > 10.6 mmol/L;

          -  Anticipated additional revascularisation within 4 months;

          -  Cardiogenic shock;

          -  Presence of other serious medical conditions

          -  Pregnancy/breast feeding

          -  Malignant hypertension

          -  End stage renal failure (creatinin > 220 micromol/l)

          -  Previous treatment with rh-EPO

          -  Blood transfusion <12 weeks prior to randomisation

          -  Polycythemia vera

          -  Previous acute myocardial infarction

          -  Concomitant inflammatory or malignant disease

          -  Recent trauma or major surgery

          -  Unwilling to sign informed consent

          -  Atrial fibrillation
Clinical trial NCT00466843 (phase 2, status: unknown status)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: antithymocyte globulin (atg), prednisone
SMILES: COC1=CC=CC=C1OCC(O)CO, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MDS that meets International Prognostic Scoring System (IPSS) criteria
             for low risk, intermediate-1 risk, or intermediate-2 risk. More information about this
             criterion can be found in the protocol.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

          -  Willing and able to attend study visits

          -  Willing to use acceptable forms of contraception prior to study entry and for the
             duration of the study

        Exclusion Criteria:

          -  Any serious medical illness that might limit survival to less than 2 years

          -  Any other uncontrolled condition or illness. More information about this criterion can
             be found in the protocol.

          -  Prior anti-lymphocyte serotherapy (received serum from an immunized animal)

          -  Proliferative chronic myelomonocytic leukemia

          -  MDS that is caused by radiotherapy, chemotherapy, and/or immunotherapy for cancerous
             or autoimmune diseases

          -  Previous or current cancer. More information about this criterion can be found in the
             protocol.

          -  Receiving any other investigational agents

          -  Certain abnormal lab values. More information about this criterion can be found in the
             protocol.

          -  History of a grade 2 National Cancer Institute common toxic criteria allergic reaction
             to rabbit proteins

          -  Psychiatric illness that might interfere with study participation

          -  HIV-1 infection

          -  Pregnancy or breastfeeding
Clinical trial NCT00507455 (phase 2, status: completed)
Conditions: lower urinary tract symptoms, bladder outlet obstruction
ICD codes: N40.2, N40.3, N40.0, N40.1
Drugs: solifenacin succinate, tamsulosin hydrochloride, placebo to solifenacin, placebo to tamsulosin
SMILES: O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction
             (BOO)

          -  BOO indication by a Bladder Outlet Obstruction Index (BOOI) ≥ 20

          -  Patient has a total International Prostate Symptom Score (IPPS) score of ≥ 8
             (Inclusion criteria for Baseline also)

          -  Patient had a maximum urinary flow rate of ≤ 12 mL/sec, with a voided volume of ≥ 120
             mL during free flow in a representative assessment of uroflowmetry.

        Exclusion Criteria:

          -  History of urinary retention in preceding 12 months

          -  Current urinary tract infection (UTI) or symptomatic and recurrent UTI of > 3 episodes
             within 12 months.

          -  Known clinical history or diagnosis of chronic inflammation, stone in bladder or
             ureter, or other causes of outflow tract obstruction

          -  Known diagnosis or history of carcinoma or previous pelvic radiation therapy, except
             non-metastatic basal or squamous cell carcinoma of the skin that had been treated
             successfully

          -  Clinically significant cardiovascular or cerebrovascular diseases within 6 months
             prior to Visit 1
Clinical trial NCT01020331 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: memantine
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria

          1. Age 18-85

          2. Male or Female

          3. Clinically definite ALS by El Escorial criteria

          4. Elevated levels of Tau in CSF

        Exclusion Criteria:

          1. Patients with FVC below 1.5 L or who require respiratory assistance

          2. History of liver disease

          3. Severe renal failure

          4. History of intolerance to Riluzole or Memantine

          5. Any other co morbid condition which would make completion of trial unlikely

          6. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to
             use birth control.

          7. Taking any trial medications. Non-trial medications are not cause for exclusion.

          8. Unwillingness to provide consent
Clinical trial NCT00471276 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of breast cancer

          -  Metastatic or locally recurrent disease that is, in the opinion of the investigator,
             not amenable to resection or radiation therapy

          -  Patients with at least one measurable lesion as per RECIST

        Exclusion Criteria:

          -  Inflammatory breast cancer

          -  Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months
             ago)
Clinical trial NCT00104403 (phase 2, status: completed)
Conditions: nausea and vomiting, chemotherapy-induced, chemotherapy-induced nausea and vomiting
ICD codes: D61.810, D61.810
Drugs: gw679769, dexamethasone, ondansetron hydrochloride
SMILES: C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          -  Willing to provide a written informed consent prior to receiving any study-specific
             procedures or assessments.

          -  Diagnosed with a solid malignant tumor and has not previously received chemotherapy.

          -  Scheduled to receive chemotherapy conducive to regimens outlined in the study
             protocol.

        Exclusion criteria:

          -  Not received any investigational product within 30 days of enrollment into the study.

          -  Must not be pregnant.

          -  Must not be of childbearing potential or is willing to use specific barrier methods
             outlined in the protocol.

          -  Must not be scheduled to receive radiation therapy to the abdomen or to the pelvis
             within seven (7) days prior to starting study medication.

          -  Must not be currently under treatment for a condition which may cause nausea or
             vomiting (i.e., active peptic ulcer disease, gastric obstruction).

          -  Must not have a history of peptic ulcer disease.
Clinical trial NCT00633659 (phase 2, status: completed)
Conditions: vascular disease, critical lower limb ischemia
ICD codes: I73.9, D57.03, D57.213, G46.8, I73.89
Drugs: hemospan (mp4ox), voluven (hes 130/0.4)
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male or female (surgically sterile or post-menopausal) patients with CCLI that
             meet the following definition: i) History of pain at rest and/or ulceration; ii) Ankle
             systolic BP/Brachial systolic BP Index (ABI) <0.6 at the time of inclusion; iii) Ankle
             systolic BP <70 mmHg and/or toe systolic BP <50 mmHg

          -  Has received written and verbal information about the investigational product and the
             protocol by the investigator and has had the opportunity to ask questions about the
             study

          -  Patients must sign an Informed Consent Form (ICF), that has been reviewed and approved
             by the independent Ethics Committee (EC)

        Exclusion Criteria:

          -  Severe congestive heart failure (EF <40%, or New York Heart Association Class III or
             IV

          -  Any acute or chronic condition that will limit the patient's ability to complete the
             study

          -  Recent acute coronary syndrome (unstable angina or myocardial infarction [MI] within 1
             month)

          -  Severe dementia or clinically significant psychiatric disorder requiring active
             treatment

          -  Evidence of untreated or uncontrolled hypertension (SBP >180 mmHg, or DBP >100 mmHg),
             or a difference in systolic BP in each arm that is >15 mmHg (measured by cuff and a
             pen-Doppler at screening in the supine position, in both arms)

          -  Smoking or use of any nicotine-containing product (e.g., snuff) within previous 24
             hours before start of study

          -  Any systemic rheumatic disease

          -  Taking oral steroid therapy (does not include steroids taken intermittently via
             inhaler)

          -  Chronic hepatic disease (abnormal LFTs >3X upper limit of normal, known history of
             Hepatitis C or B)

          -  Chronic renal disease (creatinine >1.8 mg/dL, or known polycystic kidney disease)

          -  Expectation of poor patient compliance with study protocol

          -  Patients scheduled for surgical procedure within 7 days from start of this study

          -  Involved in any investigational drug or device trial within 30 days prior to this
             study

          -  Professional or ancillary personnel involved with this study
Clinical trial NCT00301782 (phase 2, status: completed)
Conditions: extragonadal germ cell tumor, teratoma, testicular germ cell tumor
ICD codes: E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: carboplatin, cisplatin, etoposide phosphate, vincristine sulfate
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Nonseminoma germ cell tumor of any extracranial primary site diagnosed by 1 of the
             following methods:

               -  Histologic confirmation

               -  Alpha-fetoprotein (AFP) > 1,000 ng/mL or human chorionic gonadotropin (hCG) >
                  5,000 IU/L with appropriate clinical picture in a man < 45 years of age

          -  Poor prognosis features as defined by ≥ 1 of the following:

               -  AFP > 10,000 ng/mL

               -  hCG > 50,000 IU/L

               -  Lactic dehydrogenase > 10 times normal

               -  Nonpulmonary visceral metastases

               -  Mediastinal primary site

        PATIENT CHARACTERISTICS:

          -  Male

          -  WHO performance status 0-3

          -  Glomerular filtration rate > 50 mL/min

               -  Less than 50 mL/min eligible if due to obstructive neuropathy that can be
                  relieved by stenting or nephrostomy

          -  No comorbid condition that would prevent treatment

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy except low-dose chemotherapy to stabilize disease before study
             therapy
Clinical trial NCT01314261 (phase 2, status: completed)
Conditions: chronic hepatitis c, hepatitis c virus (hcv) infection
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-267, pegylated interferon (pegifn), ribavirin (rbv)
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment naïve participants

          -  Females must be either postmenopausal for at least 2 years or surgically sterile

          -  Males must be surgically sterile or practicing specific forms of birth control

          -  Chronic hepatitis C virus (HCV), genotype-1 infected participants

          -  Documented FibroTest score in combination with an Aspartate Aminotransferase to
             Platelet Ratio Index (APRI), or a liver biopsy within the last 12 months to document
             absence of cirrhosis

        Exclusion Criteria:

          -  Pregnant or breastfeeding female

          -  Use of any medications contraindicated for use with pegylated interferon(pegIFN) or
             ribavirin (RBV) 2 weeks prior to study drug administration or 10 half-lives, whichever
             is longer

          -  Clinically significant cardiac, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic disease, or any uncontrolled medical illness
             or psychiatric disease or disorder

          -  Current or past clinical evidence of cirrhosis or bridging fibrosis

          -  Abnormal screening laboratory results
Clinical trial NCT00600821 (phase 2, status: completed)
Conditions: non-small-cell lung carcinoma, adenocarcinoma
ICD codes: D02.20, D02.21, D02.22, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: bevacizumab, carboplatin, paclitaxel, ag-013736 (axitinib), carboplatin, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced non squamous cell, lung cancer

          -  No prior treatment for lung cancer except prior adjuvant therapy if last dose was >12
             months prior to enrollment

        Exclusion Criteria:

          -  Prior therapy for advanced lung cancer

          -  The need for blood-thinners

          -  Coughing up blood